Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Drug Pricing

Friday, 17 February 2017

Sen. Tom Cotton (R-AR) announced in a Feb. 16 floor speech that he will craft a legislative solution to price hikes associated with the orphan drug program, following news of an expected increase in the cost of a newly approved drug to treat Duchenne muscular dystrophy.

Friday, 17 February 2017

An industry attorney said there is continued uncertainty over how HHS and FDA will implement 21st Century Cures language that calls for harmonization of the two regulators' human research subject protection regulations even though HHS just issued a final rule revising its regulation of the so-called Common Rule.

Wednesday, 15 February 2017

Drug spending growth slowed from 9 percent in 2015 to 6 percent last year due to a drop in use of hepatitis C drugs, according to 2016 projections that the CMS actuary's office reported Wednesday (Feb. 15).

Tuesday, 14 February 2017

The generic drug trade association is the latest group to launch a campaign touting its industry as the solution to lowering drug prices, but it is also using its new campaign to push back against certain drug pricing proposals it sees as bad for the generic market.

Tuesday, 14 February 2017

A bipartisan group of three senators, including Senate Finance member Charles Grassley (R-IA), is urging HHS Secretary Tom Price to allow imports of less-costly versions of expensive off-patent prescription drugs that lack competition, but only if the imported drugs are produced abroad by brand companies that invented the drugs or by well-known generic companies that commonly sells drugs in the United States.

Monday, 13 February 2017

Potential abuses of FDA's orphan drug program are facing more scrutiny on Capitol Hill following Marathon Pharmaceuticals' decision to charge nearly $90,000 for its corticosteroid Emfalza (deflazacort) approved by FDA Feb. 9 to treat Duchenne muscular dystrophy.

Friday, 10 February 2017

Senate Judiciary Chair Charles Grassley (R-IA) said he hopes newly confirmed HHS Secretary Tom Price will be more responsive to lawmakers' concerns than was the Obama administration, particularly around Medicaid drug rebates and misclassifications.

Friday, 10 February 2017

Marathon Pharmaceuticals is drawing ire from two health policy experts after the company announced it would charge nearly $90,000 for its newly approved corticosteroid to treat Duchenne Muscular Dystrophy.

Thursday, 09 February 2017

As attention turns to drug distribution middlemen in the debate over rising drug prices, pharmacy benefit managers have launched another coalition, and the industry’s trade group rolled out a series of new videos in its campaign to emphasize the work that pharmacy benefit managers do to lower drug prices.

Thursday, 09 February 2017

The court of appeals for the Federal Circuit on Wednesday (Feb. 8) suspended an injunction in a patent dispute that would have pulled one of the two biologics in a new category of cholesterol medications from the market.

Wednesday, 08 February 2017

A group of 31 senators led by Judiciary Committee ranking Democrat Patrick Leahy (VT) is asking Kaléo Pharmaceuticals to justify the price hike of its opioid reversal product, a naloxone auto injector called Evzio, from $690 in 2014 to a current wholesale acquisition cost (WAC) of over $4,000.

Tuesday, 07 February 2017

White House Press Secretary Sean Spicer said Tuesday (Feb. 7) that the president wants Medicare to negotiate drug prices in the way that other countries keep down their drug spending.

Monday, 06 February 2017

House Energy & Commerce Chairman Greg Walden (R-OR)'s now-stalled plan to mark up this week a new bill that would create a generic priority review voucher program as a solution to drug pricing is seen by a Democratic health care lobbyist as an orchestrated attempt by the brand industry and E&C Republicans to avoid drug pricing measures being attached to upcoming user fee reauthorizations.

Monday, 06 February 2017

The Generic Pharmaceutical Association (GPhA) is in talks with both the Trump administration and members of Congress on ways to increase generic competition, Chip Davis, GPhA president and CEO, told Inside Health Policy Feb. 2 in an exclusive interview.

Monday, 06 February 2017

Lilly USA has signed a handful of so-called value-based contracts with plans in recent years, and recent-past President Alex Azar recently discussed changes that he says would spur more of deals.

Thursday, 02 February 2017

Oncologists and pharmacists are touting an oncologist-financed paper on the pharmacy benefit manager practice of demanding retroactive concessions from pharmacies, which the paper argues are unfair.

Thursday, 02 February 2017

Republican lawmakers on the House Energy & Commerce Committee at a Feb. 1 health subcommittee hearing asked witnesses whether state Medicaid programs would be better off if they could opt out of the current Medicaid drug formulary and related rebate framework, which includes all FDA-approved drugs.

Thursday, 02 February 2017

The notion of value-based contracts remains vague, but the drug industry is pushing a raft of policies to make it easier to base drug prices on outcomes.

Thursday, 02 February 2017

The House Energy & Commerce Committee will likely move next week on a newly introduced bill that would create a priority review voucher program for generic drugs, a committee spokesperson tells Inside Health Policy, in what is viewed as a bid to prevent price hikes for brand-name drugs currently without competition.

Wednesday, 01 February 2017

A new bipartisan House bill would create a priority review voucher program for sponsors who develop generics of brand drugs currently without competition.

Pages